REDDY PHARMA SAS : revenue, balance sheet and financial ratios

REDDY PHARMA SAS is a French company founded 10 years ago, specialized in the sector Commerce de gros (commerce interentreprises) de produits pharmaceutiques. Based in RUEIL-MALMAISON (92500), this company of category PME shows in 2025 a revenue of 8.7 M€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.

Data updated on 2026-05-02

Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy

Financial history - REDDY PHARMA SAS (SIREN 814400651)
Indicator 2025 2024 2023 2022 2021 2020 2019 2018 2017
Revenue 8 670 285 € 13 990 381 € 16 916 125 € 16 034 161 € 12 956 542 € 8 306 543 € 609 150 € 114 370 € N/C
Net income 68 627 € 714 863 € -225 060 € 57 900 € 106 634 € 2 268 391 € -1 037 775 € -991 462 € -576 842 €
EBITDA -807 699 € 874 898 € 404 721 € 2 658 495 € 1 221 524 € 2 441 945 € -900 898 € -979 632 € -579 516 €
Net margin 0.8% 5.1% -1.3% 0.4% 0.8% 27.3% -170.4% -866.9% N/C

Revenue and income statement

In 2025, REDDY PHARMA SAS achieves revenue of 8.7 M€. Over the period 2018-2025, the company shows strong growth with a CAGR (compound annual growth rate) of +85.6%. Significant drop of -38% vs 2024. After deducting consumption (6.6 M€), gross margin stands at 2.1 M€, i.e. a rate of 24%. This ratio measures the ability to generate value from commercial activity. EBITDA (= Gross margin - Personnel expenses - Taxes) reaches -808 k€, representing -9.3% of revenue. Warning negative scissor effect: despite revenue change (-38%), EBITDA varies by -192%, reducing margin by 15.6 pts. This reflects costs rising faster than revenue. Negative EBITDA means operations do not cover current expenses: concerning situation. Ultimately, net income (= EBIT +/- financial result +/- exceptional - corporate tax) amounts to 69 k€, i.e. 0.8% of revenue. This profit can be retained or distributed to shareholders.

Revenue (2025) ?
Revenue
Definition
Total amount of sales of goods and services made by the company.
Formula
Sales of goods + Sold production

8 670 285 €

Gross margin (2025) ?
Gross margin
Definition
Difference between revenue and cost of goods sold.
Formula
Revenue - Cost of goods consumed

2 084 059 €

EBITDA (2025) ?
Gross Operating Surplus (EBITDA)
Definition
Resources generated by current operations, before depreciation and financial expenses.
Formula
Value added - Personnel expenses - Taxes
Interpretation
Positive = profitable activity

-807 699 €

EBIT (2025) ?
EBIT (Operating Income)
Definition
Operating income, including depreciation and provisions.
Formula
EBITDA - Depreciation and provisions + Reversals

83 014 €

Net income (2025) ?
Net income
Definition
Profit or loss after all expenses, including taxes and exceptional items.
Formula
Current income + Exceptional income - Income tax

68 627 €

EBITDA margin (2025) ?
EBITDA margin
Definition
Measures the company's operating profitability.
Formula
(EBE / CA) x 100
Interpretation
> 10% : Good profitability
5-10% : Average
< 5% : Low

-9.3%

Loading income statement...

Chart evolution

Show :

Assets

Loading data...

Liabilities

Loading data...

Solvency and debt ratios

The debt ratio (= Financial debt / Equity x 100) stands at 0%. This very low level reflects a solid financial structure, offering significant room for future investments or acquisitions. Financial autonomy (= Equity / Total assets x 100) reaches 49%. This high autonomy means the company finances most of its assets through equity, a sign of strength.

Debt ratio (2025) ?
Debt ratio
Definition
Measures the proportion of debt to equity.
Formula
(Financial debt / Equity) x 100
Interpretation
< 50% : Low
50-100% : Moderate
> 100% : High

0.0%

Financial autonomy (2025) ?
Financial autonomy
Definition
Share of equity in the company's total financing.
Formula
(Equity / Total assets) x 100
Interpretation
> 30% : Good autonomy
20-30% : Average
< 20% : Low

48.971%

Cash flow / Revenue (2025) ?
Cash flow / Revenue
Definition
Self-financing capacity relative to revenue.
Formula
(CAF / CA) x 100
Interpretation
The higher the ratio, the more cash the company generates

-9.479%

Repayment capacity (2025) ?
Repayment capacity
Definition
Number of years needed to repay debts with cash flow.
Formula
Financial debt / Cash flow
Interpretation
< 3 years : Excellent
3-5 years : Fair
> 5 years : Warning

0.0

Asset age ratio (2025) ?
Asset age ratio
Definition
Measures the degree of wear of tangible assets.
Formula
Accumulated depreciation / Gross fixed assets x 100
Interpretation
< 50% : Recent assets
50-70% : Normal wear
> 70% : Aging assets

15.9%

Solvency indicators evolution
REDDY PHARMA SAS

Sector positioning

Debt ratio
0.0 2025
2023
2024
2025
Q1: 0.0
Med: 3.67
Q3: 28.55
Excellent

In 2025, the debt ratio of REDDY PHARMA SAS (0.00) ranks in the bottom 25% of the sector, which is positive. This ratio measures the weight of debt relative to equity. A low ratio indicates a solid financial structure with little dependence on creditors.

Financial autonomy
48.97% 2025
2023
2024
2025
Q1: 26.28%
Med: 43.48%
Q3: 62.04%
Good +5 pts over 3 years

In 2025, the financial autonomy of REDDY PHARMA SAS (49.0%) ranks above the median of the sector. This ratio represents the share of equity in total financing. This comfortable position offers an appreciable safety margin.

Repayment capacity
0.0 years 2025
2023
2024
2025
Q1: 0.0 years
Med: 0.0 years
Q3: 0.67 years
Excellent

In 2025, the repayment capacity of REDDY PHARMA SAS (0.00) ranks in the bottom 25% of the sector, which is positive. This ratio indicates the number of years needed to repay debt with cash flow. A short capacity reflects controlled debt and good cash generation.

Liquidity ratios

The liquidity ratio (= Current assets / Current liabilities) stands at 133.36. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months.

Liquidity ratio (2025) ?
Liquidity ratio
Definition
Ability to meet short-term debts with current assets.
Formula
Current assets / Current liabilities
Interpretation
> 1.5 : Very good
1-1.5 : Fair
< 1 : Liquidity risk

133.359

Interest coverage (2025) ?
Interest coverage
Definition
Ability to cover interest charges with operating income.
Formula
EBIT / Interest expenses
Interpretation
> 3 : Comfortable
1.5-3 : Acceptable
< 1.5 : Risk

-0.004

Liquidity indicators evolution
REDDY PHARMA SAS

Sector positioning

Liquidity ratio
133.36 2025
2023
2024
2025
Q1: 147.44
Med: 215.05
Q3: 310.05
Watch -14 pts over 3 years

In 2025, the liquidity ratio of REDDY PHARMA SAS (133.36) ranks in the bottom 25% of the sector. This ratio measures the ability to cover short-term debt with current assets. A ratio below 1 may signal potential cash flow tensions.

Interest coverage
-0.0x 2025
2023
2024
2025
Q1: 0.0x
Med: 0.36x
Q3: 5.44x
Average -8 pts over 3 years

In 2025, the interest coverage of REDDY PHARMA SAS (-0.0x) ranks below the median of the sector. This ratio indicates how many times operating income covers interest expenses. An improvement would strengthen the competitive position.

Working capital requirement (WCR) and payment terms

Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments. Average customer payment term: 70 days (formula: Customer receivables / Revenue incl. VAT x 360). Supplier term: 303 days. Excellent situation: suppliers finance 233 days of the operating cycle (retail model). Inventory turnover is 254 days (= Average inventory / Cost of goods x 360). This high level ties up cash and potentially creates obsolescence risk. Overall, WCR represents 258 days of revenue, i.e. 6.2 M€ to permanently finance.

Operating WCR (2025) ?
Operating WCR
Definition
Financing requirement generated by the operating cycle (inventory + receivables - trade payables).
Formula
Inventory + Customer receivables - Trade payables
Interpretation
Negative = cash released
Positive = financing needed

6 208 271 €

Customer credit (2025) ?
Customer credit (days)
Definition
Average payment term granted to customers.
Formula
(Customer receivables / Revenue incl. VAT) x 360
Interpretation
< 45j : Good
45-60j : Average
> 60j : Long

70 j

Supplier credit (2025) ?
Supplier credit (days)
Definition
Average payment term obtained from suppliers.
Formula
(Trade payables / Purchases incl. VAT) x 360
Interpretation
The longer the term, the better for cash flow

303 j

Inventory turnover (2025) ?
Inventory turnover (days)
Definition
Average storage duration for goods or materials.
Formula
(Inventory / Cost of goods) x 360
Interpretation
The lower the ratio, the faster the turnover

254 j

WCR in days of revenue (2025) ?
WCR in days of revenue
Definition
Expresses working capital requirement in days of revenue.
Formula
(Operating WCR / Revenue) x 360
Interpretation
The fewer days, the better the working capital management

258 j

WCR and payment terms evolution
REDDY PHARMA SAS

Positioning of REDDY PHARMA SAS in its sector

Comparison with sector Commerce de gros (commerce interentreprises) de produits pharmaceutiques

Valuation estimate

Based on 124 transactions of similar company sales (all years), the value of REDDY PHARMA SAS is estimated at 1 130 480 € (range 609 386€ - 3 438 290€). The price/revenue ratio is 0.21x (conservative valuation). This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.

Estimated enterprise value 2025
124 transactions
609k€ 1130k€ 3438k€
1 130 480 € Range: 609 386€ - 3 438 290€
NAF 5 all-time

Valuation detail by method

Ajustez les pondérations selon votre analyse

Revenue Multiple 30%
8 670 285 € × 0.21x
Estimation 1 846 549 €
1 001 340€ - 5 593 227€
Net Income Multiple 20%
68 627 € × 0.8x
Estimation 56 378 €
21 458€ - 205 886€

Valuation evolution

How is this estimate calculated?

This estimate is based on the analysis of 124 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.

  • EBITDA Multiple: Preferred method for profitable SMEs. EBITDA reflects the ability to generate cash.
  • Revenue Multiple: Used for growing companies or those with low profitability. Reflects commercial potential.
  • Net Income Multiple: Relevant for mature companies with stable results.

This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).

Similar companies (Commerce de gros (commerce interentreprises) de produits pharmaceutiques)

Compare REDDY PHARMA SAS with other companies in the same sector:

Voir toutes les statistiques du secteur Commerce de gros (commerce interentreprises) de produits pharmaceutiques

Frequently asked questions about REDDY PHARMA SAS

What is the revenue of REDDY PHARMA SAS ?

The revenue of REDDY PHARMA SAS in 2025 is 8.7 M€.

Is REDDY PHARMA SAS profitable?

Yes, REDDY PHARMA SAS generated a net profit of 69 k€ in 2025.

Where is the headquarters of REDDY PHARMA SAS ?

The headquarters of REDDY PHARMA SAS is located in RUEIL-MALMAISON (92500), in the department Hauts-de-Seine.

Where to find the tax return of REDDY PHARMA SAS ?

The tax return of REDDY PHARMA SAS is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).

In which sector does REDDY PHARMA SAS operate?

REDDY PHARMA SAS operates in the sector Commerce de gros (commerce interentreprises) de produits pharmaceutiques (NAF code 46.46Z). See the 'Sector positioning' section above to compare the company with its competitors.